Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis
Overview
Describes a thaw/wash method for CAR-T cells for intracranial delivery. B7-H3-CAR T cells were generated and expanded in G-Rex® culture devices using X-VIVO 15 media with cytokines.
What this paper found
A simple thaw/wash procedure removed nearly all DMSO from cryopreserved B7-H3-CAR T cell products while keeping them viable, sterile and functional for intracranial delivery to children with brain tumors. Thawed cells were equilibrated for 5 minutes with one volume of preservative-free normal saline, diluted with eight further volumes, washed by centrifugation and concentrated to a dose of 30 × 10^6 cells in 2 mL. Calculated DMSO fell from 5% to 0.0125–0.025%. In three validation products, final viability averaged 85.3% and viable cell recovery 76.5% of pre-cryopreservation values, endotoxin stayed at or below 0.05 EU/mL and sterility cultures were negative. Three hours after thaw, mean viability was 80.0%, and CAR/41BBL co-expression and killing of B7-H3-positive THP-1 cells matched unwashed controls.
Note: The procedure is manual and multistep; the authors note it may not be ideal for later-phase clinical studies or FDA-approved CAR T cell products and that the process needs further optimization.
Although the DMSO safety limit for IC infusion is not known, this method successfully reduced DMSO% as calculated to less than 0.025% below the internally set limit of 0.5%. — Salem Akel, Leigh Poston, Jeoungeun J. Park, Susan B. Schoultz, Lina Alloush, Fei Zheng, Sheng Zhou, Timothy Lockey, Catherine Willis, Christopher DeRenzo, Stephen Gottschalk, Cytotherapy
Study details
- Authors
- Salem Akel, Leigh Poston, Jeoungeun J. Park, Susan B. Schoultz, Lina Alloush, Fei Zheng, Sheng Zhou, Timothy Lockey, Catherine Willis, Christopher DeRenzo, Stephen Gottschalk
- Institution
- Human Applications Laboratory, St. Jude Children’s Research Hospital, Memphis, TN, United States · Experimental Cellular Therapeutic Laboratory, St. Jude Children’s Research Hospital, Memphis, TN, United States · Therapeutics Production and Quality, St. Jude Children’s Research Hospital, Memphis, TN, United States · Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, TN, United States
- Journal
- Cytotherapy
- Year
- 2023
- Cell type(s)
- CAR T Cells
- Application area
- Solid tumor
- Study phase
- Preclinical
How G-Rex® was used
After transduction with a B7-H3-CAR lentiviral vector, the T cells were seeded and expanded in G-Rex® culture devices (Wilson Wolf) in X-VIVO 15 with 5% human AB serum and 10 ng/mL IL-7 and IL-15. Cytokines were replenished after 3 to 4 days, and the CAR T cells were harvested on day 7 or 8 and cryopreserved in freezing medium containing 5% DMSO. These cGMP-manufactured products were the starting material for the thaw/wash procedure.
Explore related
Full citation
Akel S, Poston L, Park JJ, et al. Preparation of cryopreserved chimeric antigen receptor T cells for the locoreogional delivery to the neural axis. Cytotherapy. 2023;25(11):1149-1154.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.